EUCTR2020-004853-59-GR进行中（未招募）1 期
ZEUS - Effects of ziltivekimab versus placebo on cardiovascular outcomes in participants with established atherosclerotic cardiovascular disease, chronic kidney disease and systemic inflammation
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 6,200
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •-Chronic kidney disease defined by one of the below:
- •- eGFR greater than or equal to 15 and below 60 mL/min/1.73 m^2 (using the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) creatinine equation)
- •- UACR above or equal to 200 mg/g and eGFR above or equal to 60 mL/min/1.73 m2 (using the CKD-EPI creatinine equation).
- •- Serum hs-CRP greater than or equal to 2 mg/L
- •- Evidence of ASCVD by one or more of the following:
- •a)Coronary heart disease defined as at least one of the following:
- •i.Documented history of MI
- •ii.Prior coronary revascularisation procedure
- •iii.greater than or equal to 50% stenosis in major epicardial coronary artery documented by cardiac catheterisation or CT coronary angiography
- •b)Cerebrovascular disease defined as at least one of the following:
- •i.Prior stroke of atherosclerotic origin
- •ii.Prior carotid artery revascularisation procedure
- •iii.greater than or equal to 50% stenosis in carotid artery documented by X-ray angiography, MR angiography, CT angiography or Doppler ultrasound.
- •c)Symptomatic peripheral artery disease (PAD) defined as at least one of the following:
- •i.Intermittent claudication with an ankle-brachial index (ABI) below or equal to 0.90 at rest
- •ii.Intermittent claudication with a greater than or equal to 50% stenosis in peripheral artery (excluding carotid) documented by X-ray angiography, MR angiography, CT angiography or Doppler ultrasound
- •iii.Prior peripheral artery (excluding carotid) revascularisation procedure
- •iv.Lower extremity amputation at or above ankle due to atherosclerotic disease (excluding e.g. trauma or osteomyelitis).
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 1250
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 4950
排除标准
- •- Clinical evidence of, or suspicion of, active infection at the discretion of the investigator.
- •- Myocardial infarction, stroke, hospitalisation for unstable angina pectoris, or transient ischaemic attack within 60 days prior to randomisation (visit 2).
- •- Planned coronary, carotid or peripheral artery revascularisation known on the day of randomisation (visit 2).
- •- Major cardiac surgical, non-cardiac surgical, or major endoscopic procedure (thoracoscopic or laparoscopic) within the past 60 days prior to randomisation (visit 2) or any major surgical procedure planned at the time of randomisation (visit 2).
研究者
相似试验
进行中（未招募）
1 期
ZEUS – A research study to look at how ziltivekimab works compared to placebo in people with cardiovascular disease, chronic kidney disease and inflammatioEUCTR2020-004853-59-BGovo Nordisk A/S6,200
进行中（未招募）
1 期
ZEUS – A research study to look at how ziltivekimab works compared to placebo in people with cardiovascular disease, chronic kidney disease and inflammatioAtherosclerotic cardiovascular diseaseChronic kidney disease Systemic inflammationMedDRA version: 21.1Level: LLTClassification code 10051615Term: Atherosclerotic cardiovascular diseaseSystem Organ Class: 100000004866MedDRA version: 23.1Level: PTClassification code 10064848Term: Chronic kidney diseaseSystem Organ Class: 10038359 - Renal and urinary disordersMedDRA version: 20.1Level: LLTClassification code 10067394Term: hs-CRP increasedSystem Organ Class: 100000004848MedDRA version: 21.0Level: LLTClassification code 10011418Term: CRP increasedSystem Organ Class: 100000004848EUCTR2020-004853-59-ESovo Nordisk A/S6,200
进行中（未招募）
1 期
ZEUS – A research study to look at how ziltivekimab works compared to placebo in people with cardiovascular disease, chronic kidney disease and inflammatioAtherosclerotic cardiovascular diseaseChronic kidney disease Systemic inflammationMedDRA version: 26.0Level: LLTClassification code 10051615Term: Atherosclerotic cardiovascular diseaseSystem Organ Class: 10047065 - Vascular disordersMedDRA version: 23.1Level: PTClassification code 10064848Term: Chronic kidney diseaseSystem Organ Class: 10038359 - Renal and urinary disordersMedDRA version: 20.1Level: LLTClassification code 10067394Term: hs-CRP increasedSystem Organ Class: 10022891 - InvestigationsMedDRA version: 21.0Level: LLTClassification code 10011418Term: CRP increasedSystem Organ Class: 10022891 - InvestigationsEUCTR2020-004853-59-LTovo Nordisk A/S6,200
进行中（未招募）
1 期
ZEUS – A research study to look at how ziltivekimab works compared to placebo in people with cardiovascular disease, chronic kidney disease and inflammatioAtherosclerotic cardiovascular diseaseChronic kidney disease Systemic inflammationMedDRA version: 26.0Level: LLTClassification code 10051615Term: Atherosclerotic cardiovascular diseaseSystem Organ Class: 10047065 - Vascular disordersMedDRA version: 23.1Level: PTClassification code 10064848Term: Chronic kidney diseaseSystem Organ Class: 10038359 - Renal and urinary disordersMedDRA version: 20.1Level: LLTClassification code 10067394Term: hs-CRP increasedSystem Organ Class: 10022891 - InvestigationsMedDRA version: 21.0Level: LLTClassification code 10011418Term: CRP increasedSystem Organ Class: 10022891 - InvestigationsEUCTR2020-004853-59-DKovo Nordisk A/S6,200
进行中（未招募）
1 期
ZEUS – A research study to look at how ziltivekimab works compared to placebo in people with cardiovascular disease, chronic kidney disease and inflammatioEUCTR2020-004853-59-CZovo Nordisk A/S6,200